Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-29T02:21:23.032Z Has data issue: false hasContentIssue false
  • English
  • Français

Are oxidative stress markers useful to distinguish schizoaffective disorder from schizophrenia and bipolar disorder?

Published online by Cambridge University Press:  09 September 2013

Feridun Bulbul ,
Osman Virit ,
Gokay Alpak ,
Ahmet Unal ,
Mahmut Bulut ,
Mehmet Cemal Kaya ,
Abdurrahman Altindag ,
Hakim Celik  and
Haluk A. Savas
Feridun Bulbul*
Affiliation:
Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey
Osman Virit
Affiliation:
Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey
Gokay Alpak
Affiliation:
Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey
Ahmet Unal
Affiliation:
Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey
Mahmut Bulut
Affiliation:
Department of Psychiatry, School of Medicine, Dicle University, Dicle, Turkey
Mehmet Cemal Kaya
Affiliation:
Department of Psychiatry, School of Medicine, Dicle University, Dicle, Turkey
Abdurrahman Altindag
Affiliation:
Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey
Hakim Celik
Affiliation:
Department of Biochemistry, School of Medicine, Harran University, Harran, Turkey
Haluk A. Savas
Affiliation:
Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey
*
Feridun Bulbul, Department of Psychiatry, School of Medicine, Gaziantep University, 27310 Şahinbey, Gaziantep, Turkey. Tel: +0342 3606060/76362; Fax: +0342 3603928; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Schizoaffective disorder is a disease with both affective and psychotic symptoms. In this study, we aimed to compare oxidative metabolism markers of schizoaffective disorder, bipolar disorder and schizophrenic patients. Furthermore, we also aimed to investigate whether schizoaffective disorder could be differentiated from schizophrenia and bipolar disorder in terms of oxidative metabolism.

Methods

Total oxidant status (TOS) and total antioxidant status (TAS) were measured in the blood samples that were collected from schizoaffective patients (n = 30), bipolar disorder patients (n = 30) and schizophrenic patients (n = 30). Oxidative stress index (OSI) was calculated by dividing TOS by TAS.

Results

TOS and OSI were found to be higher in patients with schizoaffective disorder compared with those in schizophrenia and bipolar disorder patients. TAS was not significantly different between the groups.

Conclusion

Schizoaffective disorder was found to be different from bipolar disorder and schizophrenia in terms of oxidative parameters. This result may indicate that schizoaffective disorder could differ from bipolar disorder and schizophrenia in terms of biochemical parameters. Increased TOS levels observed in schizoaffective disorder may suggest poor clinical course and may be an indicator of poor prognosis.

Keywords

bipolar disorderoxidative metabolismoxidative stressschizoaffective disorderschizophrenia
Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 26 , Issue 2 , April 2014 , pp. 120 - 124
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Crow, TJ. Nature of the genetic contribution to psychotic illness a continuum viewpoint. Acta Psychiatr Scand 1990;81:401–408.Google Scholar
2.Cheniaux, E, Landeira-Fernandez, J, Telles, LLet al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord 2008;106:209–217.Google Scholar
3.Gergerlioglu, HS, Savas, HA, Bulbul, F, Selek, S, Uz, E, Yumru, M. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:697–702.Google Scholar
4.Yumru, M, Savas, HA, Kalenderoglu, A, Bulut, M, Celik, H, Erel, O. Oxidative imbalance in bipolar disorder subtypes: a comparative study. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1070–1074.Google Scholar
5.Virit, O, Altindag, A, Yumru, Met al. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009;60:87–93.Google Scholar
6.Erel, O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004;37:277–285.Google Scholar
7.Erel, O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103–1111.Google Scholar
8.Kosecik, M, Erel, O, Sevinc, E, Selek, S. Increased oxidative stress in children exposed to passive smoking. Int J Cardiol 2005;100:61–64.Google Scholar
9.Erel, O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112–119.Google Scholar
10.Derin, D, Yazici, A, Erkoc, S. The investigation of free radical metabolism and antioxidant defense systems elements in patients with schizophrenic disorder. Bull Clin Psychopharmacol 2001;11:174–182.Google Scholar
11.Akyol, O, Herken, H, Uz, Eet al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:995–1005.CrossRefGoogle Scholar
12.Yanik, M, Vural, H, Kocyigit, Aet al. Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology 2003;47:61–65.Google Scholar
13.Zoroglu, SS, Herken, H, Yurekli, Met al. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiat Res 2002;36:309–315.Google Scholar
14.Ustundag, B, Atmaca, M, Kırtas, O, Selek, S, Metin, K, Tezcan, E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci 2006;60:458–464.Google Scholar
15.Othmen, LB, Mechri, A, Fendri, Cet al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:155–159.Google Scholar
16.Savas, HA, Gergerlioglu, HS, Armutcu, Fet al. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 2006;7:51–55.Google Scholar
17.Machado-Vieira, R, Andreazza, AC, Viale, CIet al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007;421:33–36.Google Scholar
18.Selek, S, Savas, HA, Gergerlioglu, HS, Bulbul, F, Uz, E, Yumru, M. Probable oxidative imbalance in bipolar depression: the course of nitric oxide and superoxide dismutase during the treatment of depressive episode. J Affect Disord 2008;107:89–94.CrossRefGoogle ScholarPubMed
19.Kuloglu, M, Ustundag, B, Atmaca, Met al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002;20:171–175.Google Scholar
20.Frey, BN, Andreazza, AC, Kunz, Met al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:283–285.Google Scholar
21.Ozcan, ME, Gulec, M, Ozerol, E, Polat, R, Akyol, O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004;19:89–95.Google Scholar
22.Wang, JF, Shao, L, Sun, Xet al. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009;11:523–529.Google Scholar
23.Raffa, M, Barhoumi, S, Atig, F, Fendri, C, Kerkeni, A, Mechri, A. Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:371–375.Google Scholar